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Despite an increasing need for clinical trials involving people living with HIV (PLWH), little 
is known about how PLWH experience trial closure, particularly in low income countries, 
where the majority of trials take place. We sought to explore the impact of trial closure on 
PLWH in Uganda. This was an interpretive, grounded theory study using in-depth interviews, 
conducted between October 2014 and August 2015. Adult participants (N = 23) from 3 trials 
were included. The findings indicated that trial closure was represented as “moving to 
another world” and was an emotional transition, linked to a loss of quality care in the 
research environment, the need to find alternative health facilities, fear of experiencing 
unwanted side effects, a desire to receive trial feedback, and difficulties linking to post-trial 
care. We concluded that PLWH leaving trials in a resource-limited setting required holistic 
care to facilitate their transition back to “usual care.”  
 




Moving to another world: Understanding the impact of clinical trial closure on research 
participants living with HIV in Uganda 
HIV remains a global threat despite prevention and treatment innovations to curb the 
epidemic (Global Estimates of Disease 2015 HIV Collaborators, 2016). The research 
underpinning the majority of new innovations has been conducted in resource-poor settings, 
and all are potentially associated with uncertain side effects, both in the long and short term 
(Sofaer et al., 2009). Given the potential impact of new technologies and treatments on 
quality of life for trial participants, it is important to elicit the experiences and concerns of 
those who take part in HIV clinical trials and other relevant stakeholders.  
Qualitative research has been suggested as an appropriate means for undertaking such 
investigations (Department of Health [DoH], 2010), and several such studies (Essack et al., 
2010; Vallely et al., 2009) have now been conducted. However, most of these studies have 
involved non-research participants (i.e., general community members) sharing their views on 
scenarios or hypothetical issues that might arise from hypothetical research participation, or 
non-community stakeholders (e.g., research professionals, health care providers, or policy 
makers). Limited studies have been undertaken with participants who have actually taken part 
in a clinical trial. Those that have, have mainly focused on (a) exploring reasons for trial 
participation (MacPhail, Delany-Moretlwe, & Mayaud, 2012; Woodsong et al., 2012) to 
address concerns about meeting trial recruitment targets, or (b) experiences during the 
conduct of a trial (Kacanek et al., 2012; Stadler, Delany, & Mntambo, 2008; Tarimo et al., 
2011). Far fewer studies have explored the experience of clinical trial closure, as highlighted 
in a recent systematic review, which found no studies that examined the experience of HIV 
trial exit or transition back to usual care (Nalubega & Evans, 2015). This is a key gap. 
Several authors have observed that the area of post-trial care has been neglected in 
policy, practice, and research (Pratt et al., 2012; Wilson, Elkan, & Cox, 2007). Post-trial care 
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appears to have been paid limited attention compared to other areas, such as informed 
consent, standards of care during research, and monitoring and management of adverse 
effects during trial conduct. This gap was also identified in a trial document review by 
Ciaranello et al. (2009), which aimed to establish the ways in which post-trial services were 
described in protocols and informed consent forms of antiretroviral clinical trials. Their 
review found that fewer than 50% of the documents included details or plans regarding post-
trial care, compared to other aspects of the research, which received considerable attention. 
Similarly, in a systematic survey to establish the reporting of informed consent, standard of 
care, and post-trial obligations in global registers of randomized control trials in the fields of 
HIV, malaria, and tuberculosis trials, Cohen, O'Neill, Joffres, Upshur, and Mills (2009), 
reported that only 1% of trials described provisions for post-trial benefits. Another study by 
Shah, Elmer, and Grady (2009), which assessed 18 studies in order to examine whether the 
National Institutes of Health (NIH) guidance document was being implemented in NIH-
funded antiretroviral therapy (ART) trials conducted in developing countries, found that none 
had a guarantee for long-term sponsor funding after the trials, which limited post-trial care.  
Recommendations regarding improvements to post-trial care in non-HIV studies have 
been made by several authors. For example, a review by Wilson et al. (2007), regarding 
closure for patients at the end of cancer clinical trials, concluded that researchers should 
develop specific post-trial care practices (i.e., transition discussions and feedback on the 
outcomes of trial treatments) to promote participant wellbeing and to enable them to cope 
with termination of the trial. Similarly, Sofaer et al. (2009), recommended systematic and 
consistent discussions on post-trial obligations with potential participants beginning at the 
informed consent process, because this was thought to alleviate participant post-trial anxieties 
and increase trust in the research.  
Raising an additional dimension, Pratt et al. (2012), argued that current ethical 
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guidelines on post-trial obligations may be overly generic and, in particular, may be not be 
suited to the realities of research practice in low-income settings. The authors identified a 
need to develop post-trial guidelines that were sensitive to local contexts and to the specific 
needs of different groups of participants. For example, research conducted in low-income 
settings may necessitate more supportive approaches during trial closure, owing to the 
impoverished socio-economic status of local communities and to disparities in the quality of 
care between Trial Health Care Facilities (THF) and Other Health Care Facilities (OHF), 
which can include government as well as voluntary sector provision. Such guidelines, they 
argued, should be developed collaboratively by a range of different stakeholders such as the 
government, researchers, communities, and research sponsors (Pratt et al., 2012). Other 
authors have noted that research involving chronic conditions such as HIV, carried additional 
post-trial obligations for researchers, as participants might require ongoing care or treatment 
following study termination (Sofaer et al., 2009; Unguru, Joffe, Fernandez, & Yu, 2013). 
This is also the case for HIV drug trials, where there is a need for continuity of HIV treatment 
and where questions have arisen following trial closures regarding ongoing access to trial 
drugs and the incidence and management of unknown side effects of trial drugs, especially 
when these may not occur for many years (Joint United Nations Programme on HIV/AIDS 
[UNAIDS], 2012; Sofaer et al., 2009).  
Despite calls to improve and clarify post-trial care policies and practices for HIV 
research in resource-poor settings, there is a dearth of evidence regarding patient experiences 
during HIV trial closure and post-trial care. Such research is essential to underpin future 
guideline development in this area.  
Research Aim 
We aimed to establish the impact of HIV clinical trial closure on people living with 
HIV (PLWH) in Uganda. This paper is part of a larger study that aimed to explore how care 
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was perceived and enacted in HIV drug trial closure from the perspectives of trial participants 
and research staff in Uganda (Nalubega, 2017). The motivation to undertake this research 
stemmed from the first author’s experience working as a research nurse in numerous HIV 
clinical trials, where she witnessed participant distress during trial closure periods when there 
was no post-trial care plan. After a systematic review was undertaken to explore the views 
and experiences of participants in HIV research in sub Saharan Africa (Nalubega & Evans, 
2015), it was discovered that there was no empirical evidence in this area and the decision 
was made to investigate the issue further.  
Methods 
An interpretive-constructivist grounded theory approach was adopted (Charmaz, 
2014) to establish an in-depth understanding of the post-trial care experience. This method 
provided explicit but flexible analytic guidelines that directed the process of data collection, 
inductive analysis, and conceptualization (Higginbottom & Lauridsen, 2014). Pseudonyms 
are used to name respondents, the included trials, research institutions, and other health care 
facilities in order to maintain anonymity. The methods reported in this paper have been 
reported in detail elsewhere (Nalubega, 2017).  
Research Setting 
The study included participants from three trials (Trial 1, Trial 2, Trial 3), from two 
different research institutions, referred to as A and B. Trial 1 and Trial 3 were conducted in 
two different sites in institution A: Trial 1 was conducted at an urban site, situated in 
Kampala, the capital city of Uganda, and Trial 3 was conducted at a peri-urban site, in the 
eastern part of Uganda. Trial 2 was conducted in institution B, at a peri-urban site located in 
the western part of Uganda. The three trials were conducted in different social settings, 
providing a diversity of views and experiences. The trial characteristics and settings are 
summarized in Table 1 below. 
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Table 1  
Characteristics of Included Trials 
Characteristic Trial 1 Trial 2 Trial 3 
Research aim (main 
objective) 
Test different second 
line therapies in 
patients failing on a 
first line regimen in 
Africa 
Evaluate the safety of 
discontinuing 
cotrimoxazole 
prophylaxis in adult 
PLWH on ART in 
Uganda 
Investigate 3 methods 
to reduce early 
mortality in 
individuals starting 
ART with severe 
immunodeficiency 
Immune/health 
status of trial 
participants at 
recruitment  
All participants were 
living with HIV and 
immune suppressed 
after first line regimen 
treatment failure  
All participants were 
living with HIV and 
had achieved sustained 
immune restoration  
All participants were 
living with HIV, with 
severe immune 
deficiency  













trial participation  
Contact with pre-
trial HIV treatment 
facilities during 
research 
No contact retained  Retained contact in 
routine checkups 
every 3 months at 
these facilities  
No contact (there were 
no pre-trial HIV care 
providers) 
Access to HIV care 
and treatment during 
research 
Received all HIV-
related care and 
treatment from the 
research site  
Received trial regimen 
and all treatment 
related to OIs from the 
research site; routine 
HIV care and ART 
obtained from pre-trial 
care facilities 
Received all HIV-
related care and 
treatment from the 
research site  
Presence of a public 
HIV care facility 
attached to the 
research institution 
Present Not present Present 
Number of trial 
participants included 
in our study 
7 8 6 
Note. PLWH = people living with HIV; ART = antiretroviral therapy; OI = opportunistic infection. 
 
All participants were interviewed on the research site premises. Seven interviews took 
place in research rooms, seven took place in an outside shelter (tent), and seven took place 
under a tree. For all interviews, there was minimal interruption from the surrounding 
environment and the overall quality of interviews was good. All interviews took place on 




Our research was approved by the University of Nottingham United Kingdom and 
The AIDS Support Organization (TASO) Uganda ethics committees. The study was 
registered with the Uganda National Council for Science and Technology as SS 3608. All 
participating institutions provided approval for the research to be undertaken at their 
institutions and written informed consent was sought and granted by all participants. 
Pseudonyms were used throughout the research to identify participants.  
Recruitment and Data Collection Methods 
We aimed to recruit a maximum of 30 participants in our study. However, being a 
grounded theory study, the final sample size of 21 participants was linked to an assessment of 
theoretical saturation. Achieving a balance of gender and geographical setting was also taken 
into consideration. The researcher was not previously known to trial participants. To preserve 
confidentiality, participants were first contacted by their former research institutions to ask 
for permission for the researcher to approach them. This was done using phone calls or a 
home visit.  
The researcher purposefully sampled participants who met the following inclusion 
criteria: living with HIV infection, in a treatment drug trial that lasted for at least 6 months, 
and being within 3 to 12 months of trial exit. To screen for eligible trials, the researcher 
assessed seven major research institutions in Uganda; three sites from two research 
institutions had trials that met inclusion criteria. After establishing eligible trials, participants 
were selected using purposive and convenience sampling approaches. This was required as 
there were limited participants who met the inclusion criteria. For example, some participants 
in two of the included trials had already completed 12 months so these had to be excluded. 
Trial 3, which was still ongoing, had many potential participants who had not yet completed 
3 months after trial exit, hence such participants could not be included. We continued to 
screen and interview participants on an ongoing basis, based on their eligibility, availability, 
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and accessibility, and this process was guided by the participants’ former research 
institutions. Being a grounded theory study, theoretical sampling (an approach that aims to 
collect specific data about an emerging concept) was also used to gather data specific to 
particular themes as they emerged during the analysis. For example, the theme of financial 
compensation emerged during our first interviews, and we specifically assessed details about 
why, how, and when participants wished to be compensated during subsequent interviews. 
We stopped recruiting participants after realizing theoretical saturation, where further data 
did not improve the explanations/interpretations made on the categories.  
In-depth individual interviews with semi-structured interview guides were used to 
collect data from post-trial participants. Interviews lasted from 25 to 66 minutes. All 
interviews were audio-recorded and, where necessary, field notes were taken by the lead 
researcher, to summarize key points and reflections. Data collection followed an iterative 
approach, consistent with the grounded theory approach, where initial data analysis informed 
later data collection (Charmaz, 2014). All interviews were undertaken by the lead researcher, 
who was a PhD student with substantial training in qualitative research. Translators or the 
presence of a second party were not required because the interviewer was well conversant 
with the two languages (Luganda and English) used during the interviews. Data collection 
took place for 10 months, between October 2014 and August 2015.  
Data Analysis 
Interviews were transcribed and, where necessary, translated prior to analysis. All 
transcription and translation were done by the first author.  Data analysis followed the 
grounded theory approach of open coding, focused coding, axial coding, theoretical coding, 
and theory construction (Charmaz, 2014). Initial coding, using the line-by-line approach 
identified all possible meanings from the data, which helped us remain as open as possible to 
all theoretical possibilities from the data. Some of the initial codes were found to be more 
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conceptual and were used as theoretical categories. For example, an initial code of feeling 
uncertain about post-trial care, gave rise to a more theoretical code of uncertainty about 
future care and treatment, which was used in the final model. Focused coding, on the other 
hand, was undertaken to elicit more conceptual codes that represented the data. The process 
of focused coding eventually led to the identification of concepts, which were transformed 
into tentative categories. For example, a tentative category of emotional effects of research 
closure was derived from focused codes (Table 2), and was refined to going through an 
emotional turmoil, a major theme in the final model.  
 
Table 2 
An Example of How Categories Were Developed From Focused Codes 
Focused codes Tentative categories 
Feeling hopeful about research 
Feeling sad about leaving research 
Feeling bad about leaving research  
Feeling uncertain about a post-trial care institution 
Worrying about transferring to new care facility  
Feeling unhappy about research closure 
Desiring to continue research participation 
Emotional effects of research closure 
Advocating for financial support  
Importance of financial empowerment 
Encountering transportation difficulties 
Advocating for financial facilitation  
Economic implications 
 
Further analytic processes involved asking relevant questions, which enabled us to 
expand emerging theoretical interpretations, and diagram data, a process that helped us elicit 
relationships between different codes, categories, and themes. A core concept was identified 
by further refining the categories. In our research, the core concept of moving to another 
world was conceptualized from categories that implied that the process of leaving a clinical 
trial to join non-trial care appeared to be moving from a favorable to an unfavorable world, 




Maintaining Rigor  
To maximize rigor, emerging themes and interpretations were extensively discussed 
and agreed upon by the whole research team, all of whom had read the original transcripts. In 
addition, we sought to maximize credibility of the findings by ensuring that themes were well 
supported by the data and well-illustrated through participant quotes. Careful attention was 
paid to identify any disconfirming cases and to explore nuances within the themes. For 
example, participants shared opposing views about the need for financial benefits, where 
some felt it was necessary and a few felt it was not. Paying attention to divergent views 
helped to widen our overall understanding of post-trial concerns and contributed to the 
construction of the theoretical interpretation of the research findings, through careful 
documentation of the research process and discussions with the aforementioned team. 
Triangulation of the data was achieved through interviewing participants from different trials. 
Due to the widely disparate geographical residences of the research participants, it was not 
possible to undertake member checking. 
Reflexivity 
As mentioned above, the first author had worked as an HIV care and research nurse 
for more than 5 years in Uganda, and thus had considerable experience of the research topic 
and setting. She strongly felt that improvements needed to be made in research practice and 
maintained awareness of her pre-existing standpoints and of her status as a health 
professional. This was achieved through careful memo-ing and ongoing discussions with the 
research team, in which her views and interpretations were challenged and explored. 
However, her insider status was an advantage, as she was able to build rapport with 





The majority of trial participants (62%) were female. Trial participants were in the 
age range of 26 to 59 years, with the majority (67%) being 40 years and older. Only one trial 
participant had attained a university degree; the majority (67%) were educated below college 
level, having either stopped school at ordinary or primary levels, or had no education at all. 
Very few trial participants (14%) had official employment; the rest depended on small scale 
jobs, subsistence farming, or other sources of income such as support from families or 
friends. Ninety percent of the participants resided in rural or peri-urban settings. A summary 
of demographic characteristics of participants is presented in table 3. 
Table 3 
Characteristics of Participants 
Gender Male 8 
Female 13 
Ages (in years) 18-29 3 
30-39 4 
40-49 8 
> 50  6 




Education  None 2 
Primary 6 
Secondary 6 
College (non degree) 6 
University 1 
Employment None 3 
Subsistence  6 
Self-employed 5 
Employed 7 




We sought to establish how PLWH participants understood and experienced care as 
they transitioned from HIV drug trials to the public health care system or community in 
Uganda. We report findings related to one particular category, moving to another world, 
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which explains the expectations and experiences of post-trial participants during transition 
from trial to non-trial care. 
Moving to Another World  
This category conceptualized the transition of trial participants from Trial Health Care 
Facilities (THFs) to Other Health Care Facilities (OHFs) in the Ugandan context, 
representing their feelings and reactions. Participants represented the two contexts as different 
worlds, owing to the care differences. They felt that moving to an OHF required significant 
adjustment to adapt to a new world. “… it was now as if I am going to another world..., as if I 
am transferring to another generation whereby I had to begin afresh learning them slowly by 
slowly” (Wilberforce, male, 46 years, Trial 3). 
The two care contexts were considered to be substantively different in terms of care 
delivery, where the main aspects of concern were the availability of treatment (especially for 
opportunistic infections), the nature of staff interactions with clients, provision (or not) of 
incentives, and clinic waiting times. THFs were usually perceived to offer very high-quality 
care compared to OHFs and leaving a THF was highly undesirable.  
…because the problem up there [at a former OHF], when you come on a date other 
than your return date, and you haven’t been brought on a wheel chair, they mistreat 
us. You have to first sit and wait, you feel very bad and nobody cares, and they are 
telling you that you didn’t come on appointment, because they informed us that we 
should go to private facilities (whenever we are sick). … But here [in the THF], 
whenever you would come sick, the truth is that they would attend to you 
immediately and give you treatment, which the others [OHF] do not have. For them 





This perceived care gap shaped the reactions of most of the trial participants when 
faced with the reality of trial closure. The category, moving to another world, was comprised 
of two inter-linked themes. The first was related to the emotional impacts and needs of trial 
participants during the trial closure period, and the second related to the practical experiences 
and needs of participants during the process of re-linking to OHFs. Table 4 represents a 
summary of the findings presented in this paper.  
Table 4 




Going Through an 
Emotional Turmoil 
 Losing quality care and supportive relationships 
 Needing recognition 
 Uncertainty about future care and treatment 
 Fear of side effects from trial interventions 
 Anxiety of not knowing trial outcomes 
Dealing with 
Practical Challenges 
 Deciding where to seek care 
 Challenges during re-establishment of care 
 
Going Through an Emotional Turmoil 
 Trial closure often led to complex emotional reactions among the participants. Some 
of the emotions included sadness, fear, worry, uncertainty, hopelessness, and despair. These 
emotions were attributed to factors including the loss of quality care and treatment and of 
supportive relationships, the need to find alternative care, the possibility of experiencing side 
effects related to trial interventions, leaving research without knowing trial outcomes, and not 
feeling recognized for their contributions to research. Many participants expressed negative 
emotions and impacts when explaining their reactions, care expectations, needs, and 
experiences of trial closure, as noted in the following sections.  
 Loss of quality care and supportive relationships. Participants described how trial 
closure exposed them to a perceived loss of high quality care and treatment in the research 
facility and loss of other research related benefits. To many, loss of research care meant loss 
of the best (or only) available and trusted means of access to quality care. Aspects of care that 
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most participants were concerned about were the ability to obtain adequate assessment for, 
and management of, their health conditions; treatments for opportunistic infections; the 
general approach of the staff; privacy; clinic waiting times; and incentives. Participant 
narratives expressed how they missed trial-related care when the trial closed.  
I missed them [research staff], because we used to come here, few of us so they would 
care a lot for us. So they would discharge you early, and you would go home early, so 
you wouldn’t delay as they would ensure that they attend to you. So that affected me 
so much, removing me from here and sending me the other side after my time had 
ended. I wished if they could extend at least for a year. (Nabakooza, female, 54 years, 
Trial 2) 
 In addition to the loss of the quality care and of the valued relationships, participants 
also missed material benefits when trials closed, leaving them worried about how they would 
now cope. The majority of trial participants had no income, some were ill, and many 
depended on material incentives that had been provided in research. Benefits such as 
transport costs and refreshments were considered important to some participants as the quotes 
below indicate. “Yes, I missed the food assistance” (Mariako, female, 41 years, Trial 3). 
I felt bad because whenever I would come here I would be given some money. They 
would give transport, so I felt bad and I said I am going to suffer because every time I 
would collect medications, I would also receive some money. That was the main thing 
that pained me. (Nabakooza, female, 54 years, Trial 2)  
 Some participants felt a sense of abandonment when research care was discontinued, 
and more so when they perceived this to have happened abruptly. Participants felt they 
required adequate preparation by the researchers before being terminated. Others commented 
that they still needed, and deserved, the attention and care of researchers even after trial 
closure. The main reason for this was the fear that specific concerns could arise after trial 
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exit, which could only be explained or managed by researchers. They also felt this was a 
researchers’ ethical obligation.  
When they were sending off people here, the staff would inform you that, “for you, 
your time is over, go back where you came from.” They never gathered us to inform 
us that, “we are going to send you back, our research has ended here.” For me that’s 
what I thought, that they will again gather us here as they did sometime, and they tell 
us that, “now, all of you who have been getting your medications from here, you are 
going back where you came from, we have sent you off. This and this is what we have 
found.” We did not get that. … But remaining like that is like remaining hanging in 
the air. So for me, I will continue to insist, so that they can tell me the truth. If I 
encounter a problem, where can I run to? What advice? (Joel, male, 59 years, Trial 1). 
 Needing recognition. While trial participants acknowledged the voluntary nature of 
their participation, many felt their commitment and the time spent during research deserved 
to be recognized and, thus, compensated. Participants pointed out the effort they had put into 
research participation such as enduring painful procedures and frequent travel, which they 
felt deserved recognition and compensation. When this did not occur, participants felt 
disappointed as Aidah expressed:  
It (the care at closure) was not enough. Ask me why. Comparing, they would have 
thanked us, for volunteering, it is not easy. Not everyone can volunteer, maybe they 
needed to send us with some appreciation, maybe, I even don’t know how to tell this 
to you. I think they would have sent us with an appreciation. Yes, because it is not 
easy, you come under rain, you come under sunshine, you endure and continue, we 
spend a full day here, you abandon other responsibilities and you still prefer to come. 
They ask you this and the other and you endure, they prick you, and you endure, 
blood gets lost and they call you back. … It is not easy, at least you need to give a 
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person an appreciation. (Aidah, female, 46 years, Trial 2)  
 Although the majority of trial participants did not have formal employment, they still 
relied on subsistence work such as cultivation or tending to their animals, hence they felt they 
deserved to be compensated for the time they would have been doing their work. Some 
participants also felt they should be compensated for potential risks involved in research 
participation, even where no harm had occurred. In this case, participants felt the 
compensation would make up for the risk taken to participate in research and also any risks 
that might occur after trial participation:  
Sincerely - we take medications - but these medications we were taking were for 
trying (experimentation). You see it? What if you die, and leave your children, you 
see? It would be good that at the end, there would be some appreciation. So even 
though it is our lives, but they were also looking for the truth. We also cared and we 
said let us give it (life) in to establish what works. (Bettinah, female, 33 years, Trial 2) 
 Trial participants with less research experience (such as those in Trial 3) were less 
likely to express a need for compensation compared to those who had experience in other 
trials. Hence, previous research experience had an influence on post-trial care expectations. 
For example, some participants had expected to be given similar incentives as in previous 
research trials and felt disappointed when this did not happen.  
 Uncertainty about future care and treatment. Trial closures exposed participants to 
concerns about future access to HIV care and treatment. The thought of receiving lower 
standards of care in OHFs instilled fear among trial participants. In addition, some were 
worried and uncertain when they did not know what type of care to expect after leaving 
research. For example, Dennison who had no specific HIV care experience before joining 
research, appeared uncertain about his future care after leaving the research context:  
I was a bit scared (about the closure) because I knew that maybe where they are 
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taking me they will not care for me maybe the same way they have been caring for me 
here. So, I said maybe they could keep me around, they keep me around within their 
services so that I could be getting the treatment the same way they have been doing. 
Because I knew maybe when I go there, maybe they will change that style of the 
treatment, the way they have been may not remain the same. So I was not happy 
(about the closure). (Dennison, male, 46 years, Trial 3) 
 Such uncertainty resulted in participants wanting to remain in THFs and this 
influenced the choice of a post-trial care facility. Particular concerns were raised regarding 
access to treatment for opportunistic infections. By the time of trial closure, some participants 
were still experiencing ill health due to opportunistic infections and were worried about their 
continued access to treatment. Participant fears about care were partly attributed to the lack of 
availability of most treatments for opportunistic infections in Ugandan OHFs. Other concerns 
were related to long waiting hours in public health care facilities and the exposed 
environment in these facilities, associated with a fear of being seen and being stigmatized. 
Although most concerns were related to the general environment of OHFs, some participants 
were specifically worried about access to the trial regimen following trial exit. This was 
particularly a concern for Trial 1 participants who had been placed on second line HIV 
regimens, which were less likely to be available in OHFs in Uganda. “So we were wondering 
that when the study ends, shall we be able to get the real type of drugs we are on?” (Janet, 
female, 54 years, Trial 1). 
 Fear of side effects from trial interventions. Stopping trial-related care was also 
associated with fears related to the possibility of developing side effects from trial 
interventions. These fears were particularly important to participants in Trial 2, which was 
double blinded, and individuals could not easily associate side effects to a particular 
intervention or drug. These fears became more pronounced when participants felt there was 
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no opportunity to be in contact with researchers after the closure. Some challenged whether it 
was fair for the research project not to have mechanisms in place to identify and manage side 
effects that might occur after trial closure. Participants made strong recommendations to have 
post-trial follow-up care and monitoring: 
You have discontinued the person from the usual type of medication he was taking, 
and now you prepare him and exit him and inform him that “go, the research has 
ended.” When he reaches there, you would have restarted the medications he had 
stopped, you have not continued with him to know that after he has restarted it, what 
problems has he encountered. And even if he encounters a problem and returns here, 
the program would have closed, he will not find anyone to explain it to. … For me I 
would expect that, that would be the correct research that you are aware of what is 
happening until you finally close. And you come to know that after the closure up to 6 
months, what problems have been encountered by those who have participated in the 
program. (Byekwaso, male, 50 years, Trial 2) 
 Participants felt it was important for research staff to create follow-up plans, to 
monitor for possible side effects, and to continue to evaluate participant overall care and 
wellbeing following trial exit.  
… what they would have done is to continue moving, to continue inquiring to know 
after they have gone back to where they were (before joining research), how have 
they experienced life where they are; to know that what they were researching has had 
positive results or not. (Baker, male, 52 years, Trial 2) 
  
 Anxiety of not knowing trial outcomes. The need to know trial outcomes was 
expressed by participants across all trials, although there was variation regarding the timing 
and types of outcomes preferred across the different trials. Trial 1 participants, for example, 
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were particularly concerned about knowing their own personal health outcomes as a result of 
participating in the trial (rather than general trial outcomes). This could be attributed to the 
context of Trial 1, where the majority joined the trial while ill and after failing on first line 
HIV regimens. These participants’ priorities, therefore, appeared to be focused on recovery. 
Joel illustrated this while explaining the need to know trial outcomes. 
Outcomes about medications and also on our health, but mostly about our health; you 
have sent us off, but how have I gone? Have I met your expectations? When you look 
at where you found me, have I improved? But they have not informed us. We would 
like to know that, “comparing to how we got you, up to now when we are sending you 
off, for us we have seen this and this difference.” But we didn’t get that. So now, for 
me I went when I wasn’t contented. (Joel, male, 59 years, Trial 1) 
 By contrast, Trial 2 participants seemed to be more concerned about the general trial 
outcomes. This perspective could be attributed to the context of the trial, where participants 
were relatively healthy and the trial purpose was to evaluate whether cotrimoxazole could be 
safely discontinued without causing them further complications regarding HIV management. 
Many Trial 2 participants appeared anxious to know whether it was safe to discontinue this 
treatment as it would reduce their pill burdens. In addition, being a randomized controlled 
trial, participants in the treatment arm stopped taking the medication while others continued. 
However, because the trial was double blinded, participants did not know which arm they 
were in. Those who experienced ill health during research or shortly after closure expressed a 
concern of not being able to relate their current health situation to either taking, or 
withdrawing from, the treatment under investigation. This was quite a stressful experience 
and some specifically wanted to know their treatment arm.  “…and also for us to know that 
this one was on the real septirn, this one was on one without ingredients (placebo)” (Abdu, 
male, 35 years, Trial 2). 
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…so the answer we are looking for is that if a person stopped taking septrin and only 
takes ARVs (antiretrovirals), can they live? I don’t know because we didn’t come to 
know the types, that maybe one was taking this and the other without (ingredients), 
yes that is the challenge we have, we don’t know. (Aidah, female, 46 years, Trial 2) 
These findings suggested that individual participant or trial characteristics were important in 
determining the need for, and type of, trial outcomes.  
Dealing with Practical Challenges 
 In order to ensure that participants living with HIV continued to receive treatment, 
they needed to be linked to another treatment facility after trial closure. Choosing a care 
facility was an autonomous decision made by the participants, although their decisions 
depended strongly on other factors such as their health care needs and their psychosocial and 
economic contexts. Trial participants required guidance from research staff as they made 
their choices, and also needed practical support to overcome the barriers associated with 
being re-established into new care contexts.  
 Deciding where to seek care. Although participants had the choice of where to seek 
post-trial care, the process seemed challenging for many. To make their choices, trial 
participants required adequate information regarding the available care facilities. For 
example, they needed to know details about service delivery in a given facility, such as the 
availability of drugs (especially trial regimens). Research staff were expected to be well 
acquainted with such information and provide it to the participants while preparing them for 
trial exit. Such information was important because some OHFs may not have all the required 
HIV services. Although other factors were relevant, many participants indicated that the need 
for quality care was the major motivation for selecting a given care facility. Quality of care 
was mainly conceptualized in terms of how easily trial participants could access general 
health care such as medications and medical investigations, time taken at the clinic, and the 
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relationships with care providers. “The thing which made me to select this place (Institution 
A), they handled me 99, let me say 100%. The way they handled me is not like other 
hospitals, that is why I selected to stay here” (Nandi, female, 28 years, Trial 3). 
I chose to remain here (institution A) because their care was [very good], first of all I 
was used to them and I know them physically, their services, I could come, there is no 
congestion. Because the other places where they were trying to put me, I could see 
there is a lot of congestion there and a lot of time wastage there. (Dennison, male, 46 
years, Trial 3) 
 
The desire for quality care meant that some participants were prepared to accept 
significant inconvenience (such as transport costs) in order to remain close to facilities that 
they thought would offer high standards of care. However, in making their decisions, 
participants also considered other factors, such as indirect costs (e.g., of transport, loss of 
wages incurred during waiting), direct costs (e.g., having to pay for some medicines), the 
need to remain in contact with fellow trial participants, the need to receive social/family 
support, and avoiding HIV stigma.  
Challenges during re-establishment into usual care. Some participants expressed 
concerns regarding getting re-established in post-trial care facilities. For some, this involved 
going through a new, and usually difficult, (re)registration process. While the registration 
process was a particular concern for those reporting to facilities different from their pre-trial 
facilities, our findings suggested that even those returning to their former facilities (e.g., Trial 
2 participants) were worried about the process. The challenges were mainly associated with 
normal work routines and procedures (e.g., clinic hours, not working on weekends or public 
holidays), but also to facility staff attitudes and behaviors. Janet reported a bad experience 
during re-establishment into post-trial care.  
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Yes they gave me a date, and that date was a Wednesday, and when I came to this 
place, it was a tug of war. They told me, “You should go back, for us, we don’t treat 
patients on a Wednesday.” And I said, “This is what they told me; you see my form.” 
“No, Wednesday is for pregnant women,” and is it students, or youth? I still don’t 
know, I am still new in this place, but it was a tug of war. In fact, they didn’t refuse, 
but they kept on saying, “Today you are not supposed to be here, no we are not ….” 
So first day, then after they considered me and they asked me to give them the papers. 
I told them that, “I am not here by mistake, those people referred me here, maybe they 
chose a wrong date, a Wednesday, I don’t know whether they know that, …” You see 
it disturbed me so much as if I was rejected. (Janet, female, 54 years, Trial 1) 
  
 Participants who were supported by research staff to re-link to post-trial care (e.g., by 
escorting them to post-trial facilities) reported fewer challenges. Although very few reported 
such support, it was an indication that receiving research staff support or not could make a 
difference in how trial participants experienced the transition process. Participants suggested 
physical facilitation as a helpful measure to facilitate linkage to post-trial care.  
I thought that they would do one thing, when a person is transferring from here, they 
themselves would take that person. Or the others would come for him/her. For 
example, when we were coming from facility D, these people came for us themselves. 
You don’t encounter problems. (Joseph, male, 40 years, Trial 1) 
  
 Participants in Trials 2 and 3 tended to report fewer negative experiences during the 
linkage to care process compared to Trial 1. For Trial 2, this trend could be attributed to 
continued contact with their pre-trial facilities during research participation, which might 
have eased the re-establishment process because their client files remained. This finding 
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suggested that, while physical facilitation and involvement of stakeholders may be important 
strategies for facilitating linkage to post trial care, retention of contact with pre-trial care 
facilities could also be a feasible means of eliminating some of the difficulties to linkage to 
post-trial care. 
Discussion 
Our findings indicated that trial closure was experienced as a significant transition and 
emotional event. The need to leave the research facilities and return to usual care was 
described as moving to another world in which the move involved significant emotional 
turmoil and practical challenges. These were associated with the loss of quality care in the 
research environment (which was often abruptly terminated), the need to find alternative 
health facilities in Uganda, fear of experiencing unwanted clinical effects, and the need to 
receive trial feedback. The discussion below considers these issues further and identifies 
recommendations for policy and practice.  
Providing Emotional Support During Trial Closure 
Our study suggested that trial closure led to significant emotional impacts such as 
worry, fear, and anxiety among trial participants. The emotional impacts were strongly 
associated with a perceived loss of the quality of care given in THFs, which was perceived to 
be far superior to that provided in other Ugandan health care facilities. In addition, 
participants were worried about leaving research without knowing the trial outcomes, feared 
developing unwanted side effects, and feared the complex process of establishing care in 
OHFs. Similar emotional distress associated with the closure of health-related programs has 
been reported in literature with fear, anger, loss, sadness, and mourning as major reactions 
(Peck, 2007). Although limited literature exists in this area, some evidence concurs with the 
findings of our study by suggesting that during closure of research projects, loss of quality 
care is a major concern (Stephenson et al., 2008). Some authors have recommended the need 
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for psychological support from research staff, to allay fear and anxiety, and to assist them to 
find options for further access to required care (Peck, 2007; Williams, Netten, & Ware, 
2006). The loss of valued relationships, especially of research staff and peers, raised a need to 
also deal with a loss of relationships during the transition process. Respondents in our study 
suggested a need for weaning strategies to enable a planned (as opposed to an abrupt) cutoff 
from research-related care and relationships. This strategy has been suggested by other 
authors (Davis & Younggren, 2009; Wilson et al., 2007), as some evidence has indicated that 
relationships terminated abruptly were more likely to lead to negative emotions (Fragkiadaki 
& Strauss, 2012) . However, as the findings of our research suggest, little attention has been 
paid to understanding the impact of terminating close relationships in research contexts, a 
problem attributed to a lack of guidelines on this issue (Wilson et al., 2007). Understanding 
the care needs of trial participants during closure of HIV drug trials in a Ugandan setting by 
stakeholders engaged in HIV research and regulation such as HIV research organizations, 
research regulatory authorities, and the government would be a starting point to address this 
concern. 
Facilitating Linkage to, and Continuity of, Post-Trial Care 
Facilitating the linkage-to-care process emerged as a key recommendation from 
participants. Despite scant literature in this field, there have been indications that some 
participants may not subsequently engage in care following trial exit (Boghuma, 2012; 
Clouse et al., 2010). Our findings suggest a need to systematically evaluate the proportions of 
HIV trial participants who do, and do not, link back to care and to identify trial closure 
processes that are associated with higher rates of care-linkage. In addition, our study suggests 
a need to devise better approaches to support linkage to post-trial care for PLWH. 
Respondents in our study suggested a more facilitated linkage process, whereby trial facilities 
proactively ensure that trial participants were linked to, and attended, a new care facility. 
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Although there has been a lack of research about the feasibility and acceptability of this 
approach in a research context, Thompson et al. (2012) have suggested a related model to 
link PLWH to care following diagnosis.  
Findings from our research suggested the need for trial researchers to continue 
engaging with post-trial participants after they have reported to their new facilities, to ensure 
the participants have settled in and are receiving appropriate treatments and care, a finding 
that has been supported by other authors (Boghuma, 2012; Govindasamy, Ford, & Kranzer, 
2012). Nonetheless, due to limited evidence in the post-trial context, further research is 
recommended to confirm and also to validate the extent of the need for post-trial engagement 
between researchers and trial participants.  
Continuity of HIV care and treatment following research would require continuation 
of the correct HIV medications and other services. The need to provide trial medications to 
post-trial participants has been a global concern for various stakeholders and has dominated 
much of the debate on post-trial care (Haire & Jordens, 2015). Although these debates have 
focused on the need to provide trial drugs following research participation, we demonstrated 
that ex-trial participants have health care concerns that go well beyond the provision of trial 
drugs. For example, we found that, in addition to ongoing access to trial drugs, continuity of 
HIV care and treatment also required continued provision of other HIV medications 
(especially to treat opportunistic infections) and continued psychosocial and financial 
support. These findings concur with those of other authors (Grady, 2005; Stephenson et al., 
2008). Access to the medications that formed the trial intervention was of particular concern 
for those on a second line regimen, a finding similar to that of Ho (2010). This finding 
suggests that researchers may need to pay more attention to making preparations for access to 
trial medications in trials testing second- or third-line HIV medications in low income 
settings, where these drugs may not yet be widely accessible.  
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Monitoring for Possible Side Effects 
The possibility of negative effects occurring sometime after trial closure was a major 
concern for our participants, which was also documented by Nalubega and Evans (2015) and 
Sofaer et al. (2009), and authors have cited the need to attend to these needs in trial practice 
(Ho, 2010; Sofaer et al., 2009). Respondents in our study were particularly concerned about 
effects that might occur after trial participation, with a possibility of some occurring many 
years following trial closure, but most attention of researchers and regulatory authorities has 
focused on side effects occurring during trial conduct. These findings were similar to those 
identified by Sofaer et al. (2009), where participants expressed fears of problems arising after 
trial exit. Our participants wanted to be followed for as long a period as possible to capture 
any likely effects. UNAIDS (2012) also highlighted this concern and recommended particular 
focus be paid to trials that were likely to have long term effects. 
Compensation (Recognition) for Trial Participation  
Our participants voiced a desire for compensation for their contributions and 
sacrifices. The need to compensate participants in research has been extensively debated, 
with most literature suggesting similar reasons to those raised in our study (Kwagala, 
Wassenaar, & Ecuru, 2010; Uganda National Council for Science and Technology, 2007). 
Similar to our study, Njue et al. (2015) stated that poor participants required compensation 
for time spent during research participation. Despite some controversies regarding financial 
issues in research, authors have agreed that the need to compensate trial participants is 
genuine (Draper, Wilson, Flanagan, & Ives, 2009; Kwagala, Wassenaar, & Ecuru, 2010). 
Many have also agreed with the idea that determining an appropriate amount for 
compensation may require discussions between various stakeholders.  Others have suggested 
the need to consider various individual research factors such as the risks involved and the 
research context (Grady, 2005; UNAIDS, 2012).  
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The Need for Trial Feedback 
We found that HIV trial participants want to know the outcomes of the study in a 
timely manner, in order to (a) ascertain the impact of the research on their own health, (b) 
allay fears and anxieties associated with possible effects of the trial interventions, and (c) 
enable them to understand general outcomes of the trials related to the research aim. These 
findings appeared to be congruent with existing literature and research policy guidelines and 
debates, which put an emphasis on the need for dissemination of trial outcomes in research 
practice (UNAIDS, 2012; World Medical Association, 2013). Similar to findings in our 
study, it has been reported that participants need to know more specific trial outcomes such as 
treatment allocations (Armstrong et al., 2013; Cox, Moghaddam, Bird, & Elkan, 2011; Sofaer 
et al., 2009). In other studies, participants have expressed the need to know their own 
individualized trial outcomes, such as the effects of an intervention on an individual’s health 
(health outcomes) or the long term effects of their participation in the research study (Dixon-
Woods, Jackson, Windridge, & Kenyon, 2006; Fernandez et al., 2009). These concerns 
appear to suggest that trial participants require general and personal trial outcomes, a 
conclusion similar to what other authors have suggested (Cox et al., 2011; Moutel et al., 
2005) Although policy guidelines do not specifically assign the timing for providing trial 
outcomes, some have suggested the need to provide these to the participants as soon as they 
are available (UNAIDS, 2012), while others have suggested a period of at least 1 year 
following the closure of data collection (Fernandez et al., 2012). 
Limitations and Implications for Further Research 
Our study included a relatively small number of participants from one country. 
Although this number was appropriate for a qualitative grounded theory study, further 
research would be needed to assess the transferability of the findings to other settings. In 
addition, we undertook a retrospective approach so there may have been recall bias, which 
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could have affected the study findings. Finally, we included participants who were relatively 
engaged, demonstrated by a willingness to be interviewed and by the fact that they had linked 
to a post-trial care facility (even if they had experienced problems in the process). It was 
beyond the scope of our study to identify trial participants who had not been able to link to 
care, but future studies should seek to involve these individuals. 
Conclusion 
We have shown that trial closure is a complex phenomenon for PLWH in a resource 
limited setting, requiring psychological, social, and economic adjustments. Ethical 
debates/guidelines on HIV trial closure have focused on the need to ensure access to trial 
drugs after the closure; however, we have underscored the need for a more comprehensive 
approach to manage the holistic care needs of trial participants during transition from 
research to non-research care, including the careful facilitation of re-establishment into non-
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 Exiting from HIV clinical trials is a stressful event for PLWH in low income settings 
where there is disparity between care provided in research and non-research care 
facilities and, therefore, emotional support is required during the trial closure period. 
 Linking back to HIV care can be challenging for research participants who did not 
retain contact with their former care facilities; practical support should be provided 
during transition to non-research care. 
 Trial participants living with HIV require trial feedback and it is important for 
researchers to provide the feedback in a timely manner. 
 Monitoring for possible side effects from trial interventions following trial closure is a 
serious concern in trials involving PLWH and should be implemented. 
 
 
